Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled dose-ranging study of E6742 in systemic lupus erythematosus
CTR20261255Phase 2Active
- Sponsor
- Eisai Co., Ltd.
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of e6742 in systemic lupus erythematosus (SLE), sponsored by Eisai Co., Ltd.. Started Jun 2026; status: active.
02
Drugs
e6742
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20261255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261255.